Cowen analyst Joshua Jennings raised the firm’s price target on MediWound (MDWD) to $25 from $6 and keeps an Outperform rating on the shares after the FDA approved NexoBrid and triggered a $7.5M milestone from Vericel (VCEL). MediWound will benefit from high-single digit royalties on U.S. Nexobrid sales, also recently announced regulatory approvals in India and Japan and should secure EMA pediatric labeling in Q1, Jennings tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDWD:
- MediWound confirms FDA approval of NexoBrid triggers $7.5M milestone
- MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
- Vericel announces FDA approval of NexoBrid for severe thermal burns
- MediWound NexoBrid U.S. approval came ahead of schedule, says Oppenheimer
- MediWound receives FDA approval of NexoBrid for treatment of severe burns